×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NYSEARCA:XBI

SPDR S&P Biotech ETF Stock Forecast, Price & News

$77.06
+0.83 (+1.09%)
(As of 06/24/2022 04:00 PM ET)
Add
Today's Range
$74.29
$77.65
50-Day Range
$62.81
$87.77
52-Week Range
$61.78
$141.50
Volume
18.56 million shs
Average Volume
14.58 million shs
Market Capitalization
$5.97 billion
P/E Ratio
N/A
Dividend Yield
0.00%
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive XBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer SSgA
Fund NameSPDR S&P Biotech ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:XBI
Inception Date1/31/2006
Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio

Fund Focus

Asset ClassEquity
BenchmarkS&P Biotech Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$7.17 billion
Average Daily Volume$13.70 million
Discount/Premium-0.10%

ETF Expenses

Management Fee0.35%
Other Expenses0.00%
Total Expenses0.35%
Fee Waiver0.00%
Net Expenses0.35%

Administrator, Advisor and Custodian

AdministratorSSgA Funds Management, Inc.
AdvisorSSgA Funds Management, Inc.
CustodianState Street Bank and Trust Company
DistributorState Street Global Advisors Funds Distributors, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerVirtu Financial

Geographic Exposure of XBI

Currency Exposure of XBI

Sector Exposure of XBI

Industry Exposure of XBI














SPDR S&P Biotech ETF Frequently Asked Questions

How has SPDR S&P Biotech ETF's stock performed in 2022?

SPDR S&P Biotech ETF's stock was trading at $111.96 on January 1st, 2022. Since then, XBI shares have decreased by 31.2% and is now trading at $77.06.
View the best growth stocks for 2022 here
.

Who are SPDR S&P Biotech ETF's key executives?

SPDR S&P Biotech ETF's management team includes the following people:
  • James E. Ross, President, Trustee (Age 52)
  • Peter A. Ambrosini, Chief Compliance Officer (Age 69)
  • Michael P. Riley, Vice President (Age 44)
  • Gary L. French, Treasurer (Age 64)
  • John W. Clark, Assistant Treasurer (Age 46)
  • Matthew W. Flaherty, Assistant Treasurer (Age 42)
  • Chad C. Hallett, Assistant Treasurer of Street tracks series trust (Age 47)
  • Mary Moran Zeven, Secretary (Age 52)
  • Scott M. Zoltowski, Assistant Secretary (Age 44)
  • Dave Kelly, Independent Trustee

What other stocks do shareholders of SPDR S&P Biotech ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB), Walt Disney (DIS), Micron Technology (MU), Cisco Systems (CSCO), AbbVie (ABBV) and Netflix (NFLX).

What is SPDR S&P Biotech ETF's stock symbol?

SPDR S&P Biotech ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XBI."

Who are SPDR S&P Biotech ETF's major shareholders?

SPDR S&P Biotech ETF's stock is owned by a number of institutional and retail investors. Top institutional investors include Goldman Sachs Group Inc. (0.00%), Jane Street Group LLC (0.00%), Matrix Capital Management Company LP (2.52%), Clal Insurance Enterprises Holdings Ltd (2.64%), Twin Tree Management LP (0.00%) and Healthcare of Ontario Pension Plan Trust Fund (1.00%).

Which institutional investors are selling SPDR S&P Biotech ETF stock?

XBI stock was sold by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Goldman Sachs Group Inc., BlackRock Inc., Bank of Nova Scotia, UBS Group AG, Bank of America Corp DE, Cutler Group LP, and HAP Trading LLC.

Which institutional investors are buying SPDR S&P Biotech ETF stock?

XBI stock was purchased by a variety of institutional investors in the last quarter, including Matrix Capital Management Company LP, Clal Insurance Enterprises Holdings Ltd, Twin Tree Management LP, Northwestern Mutual Wealth Management Co., Jane Street Group LLC, Q Global Advisors LLC, Blackstone Inc., and Main Management ETF Advisors LLC.

How do I buy shares of SPDR S&P Biotech ETF?

Shares of XBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SPDR S&P Biotech ETF's stock price today?

One share of XBI stock can currently be purchased for approximately $77.06.

How much money does SPDR S&P Biotech ETF make?

SPDR S&P Biotech ETF (NYSEARCA:XBI) has a market capitalization of $5.97 billion.

How can I contact SPDR S&P Biotech ETF?

SPDR S&P Biotech ETF's mailing address is One Lincoln Street, Boston, 02111, United States. The official website for SPDR S&P Biotech ETF is www.spdrs.com. The exchange traded fund can be reached via phone at +1-866-7872257.

This page (NYSEARCA:XBI) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.